Hana Zensana Initial Target Market Is Breast Cancer; NDA Slated For Spring
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Hana Biosciences initially plans to target the adjuvant breast cancer market upon approval of its ondansetron oral spray formulation Zensana